A Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects Who Had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis Following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following Anti-HCV Therapy
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Emricasan (Primary)
- Indications Hepatic fibrosis
- Focus Proof of concept; Therapeutic Use
- Acronyms POLT-HCV-SVR
- Sponsors Conatus Pharmaceuticals
- 09 Apr 2018 Status changed from active, no longer recruiting to completed.
- 04 Apr 2018 Primary endpoint [Ishak Fibrosis Score (Time Frame: 24 months) ] has not been met.
- 04 Apr 2018 Results presented in a Conatus Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History